Science news

<<  return


Fewer Major Bleeds on Uninterrupted Dabigatran in AF Ablation vs Warfarin: RE-CIRCUIT


Patients who underwent ablation for atrial fibrillation had a lower incidence of major bleeding events if they received uninterrupted anticoagulation with the novel oral antagonist (NOAC) dabigatran (Praxada, Boehringer Ingelheim) than with warfarin—in what was called the first large randomized trial to compare these two strategies.

More than 600 patients were randomized and received dabigatran or warfarin starting 4 to 8 weeks before undergoing ablation until 8 weeks later, in the Dabigatran Etexilate Compared to Warfarin in Pulmonary Vein Ablation: Assessment of an Uninterrupted Periprocedural Anticoagulation Strategy (RE-CIRCUIT) trial.

Major bleeding occurred in five patients (1.6%) in the dabigatran group vs 22 patients (6.9%) in the warfarin group (P<0.001).

The data were at the American College of Cardiology (ACC) 2017 Scientific Sessions. The study was simultaneously published online in the New England Journal of Medicine.